New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:16 EDTBCRFDA posts 12-month results of C.R. Bard Levant 2 trial
The FDA posted on its website briefing documents ahead of a circulatory system devices panel meeting scheduled for June 12, where an advisory committee will review C.R. Bard's Lutonix drug-coated balloon PTA catheter. Among the documents posted was C.R. Bard's executive summary, which contains the 12-month results of its pivotal Levant 2 trial. "Freedom from TLR was numerically favorable for the Lutonix DCB group, but no statistical difference between arms in Freedom from TLR rates was observed," the company stated in the summary. Reference Link
News For BCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:37 EDTBCRC.R. Bard upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill upgraded C.R. Bard two notches to Buy from Underperform and increased its price target to $200 following Q1 results. The firm sees upside to Bard's drug eluting balloon franchise following the report and recent survey results, and expects the company to utilize its under leverage balance sheet in 2015.
April 23, 2015
17:40 EDTBCRC.R. Bard sees Q2 EPS $2.15-$2.19, consensus $2.18
Subscribe for More Information
17:29 EDTBCRC.R. Bard sees FY15 EPS $8.95-$9.05, consensus $9.00
Guidance provided on Q1 earnings conference call.
16:18 EDTBCRC.R. Bard reports Q1 adjusted EPS $2.10, consensus $2.07
Reports Q1 revenue $819.7M, consensus $813.88M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use